These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Austin CD, Gonzalez Edick M, Ferrando RE, Solon M, Baca M, Mesh K, Bradding P, Gauvreau GM, Sumino K, FitzGerald JM, Israel E, Bjermer L, Bourdin A, Arron JR, Choy DF, Olsson JK, Abreu F, Howard M, Wong K, Cai F, Peng K, Putnam WS, Holweg CTJ, Matthews JG, Kraft M, Woodruff PG, CLAVIER Investigators. Clin Exp Allergy; 2020 Dec; 50(12):1342-1351. PubMed ID: 32909660 [Abstract] [Full Text] [Related]
17. Lebrikizumab for the treatment of asthma. Antoniu SA. Expert Opin Investig Drugs; 2016 Oct; 25(10):1239-49. PubMed ID: 27554950 [Abstract] [Full Text] [Related]
18. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, Owen R, Putnam W, Castro M, DeBusk K, Lin CY, Voulgari A, Yen K, Omachi TA. J Am Acad Dermatol; 2018 May; 78(5):863-871.e11. PubMed ID: 29353026 [Abstract] [Full Text] [Related]